-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Rani Therapeutics Holdings, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from Q3 2021 to Q3 2025.
- Rani Therapeutics Holdings, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2025 was $-5,412,000, a 20.1% increase year-over-year.
- Rani Therapeutics Holdings, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 30 Sep 2025 was $-28,607,000, a 1.72% decline year-over-year.
- Rani Therapeutics Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $-30,001,000, a 11.5% increase from 2023.
- Rani Therapeutics Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $-33,910,000, a 10.6% decline from 2022.
- Rani Therapeutics Holdings, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $-30,661,000, a 268% decline from 2021.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)